Search Results - "Thoelke, A."

  • Showing 1 - 14 results of 14
Refine Results
  1. 1

    Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study by Schadendorf, D, Hauschild, A, Ugurel, S, Thoelke, A, Egberts, F, Kreissig, M, Linse, R, Trefzer, U, Vogt, T, Tilgen, W, Mohr, P, Garbe, C

    Published in Annals of oncology (01-10-2006)
    “…Background: Temozolomide has shown some efficacy in metastatic melanoma and recently received extended approval to treat brain tumours. The purpose of this…”
    Get full text
    Journal Article
  2. 2

    Primary extracutaneous malignant melanoma: a comprehensive review with emphasis on treatment by Thoelke, A, Willrodt, S, Hauschild, A, Schadendorf, D

    Published in Onkologie (01-01-2004)
    “…Extracutaneous malignant melanomas (EMM) require special consideration in the field of oncology due to their rareness and--depending on the localization--the…”
    Get more information
    Journal Article
  3. 3
  4. 4

    The influence of maternal exposure to volatile organic compounds on the cytokine secretion profile of neonatal T cells by Lehmann, I., Thoelke, A., Rehwagen, M., Rolle-Kampczyk, U., Schlink, U., Schulz, R., Borte, M., Diez, U., Herbarth, O.

    Published in Environmental toxicology (2002)
    “…Indoor VOC (volatile organic compound) exposure has been shown to be correlated with airway symptoms and allergic manifestations in children. An investigation…”
    Get full text
    Journal Article Conference Proceeding
  5. 5

    T cell reactivity in neonates from an East and a West German city – results of the LISA study by Lehmann, I., Thoelke, A., Weiss, M., Schlink, U., Schulz, R., Diez, U., Sierig, G., Emmrich, F., Jacob, B., Belcredi, P., Bolte, G., Heinrich, J., Herbarth, O., Wichmann, H.E., Borte, M.

    Published in Allergy (Copenhagen) (01-02-2002)
    “…Background: Within an ongoing birth cohort study (LISA) the cytokine production of cord blood T cells was compared between neonates from Leipzig (East Germany)…”
    Get full text
    Journal Article
  6. 6

    Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma by Fink, W, Zimpfer-Rechner, C, Thoelke, A, Figl, R, Kaatz, M, Ugurel, S, Schadendorf, D

    Published in Onkologie (01-01-2004)
    “…Stage IV melanoma has a poor prognosis with a median survival of 3-11 months from diagnosis of distant metastases. Response rates in first-line regimens range…”
    Get more information
    Journal Article
  7. 7
  8. 8

    Re: Association Between Endothelin Receptor B Nonsynonymous Variants and Melanoma Risk by Thirumaran, Ranjit K., Thoelke, Adina, Ugurel, Selma, Hemminki, Kari, Schadendorf, Dirk, Kumar, Rajiv

    “…The known genetic risk factors for malignant melanoma, besides CDKN2A and CDK4 mutations, include variant alleles of the melanocortin-1 receptor (MC1R) gene. A…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11

    Clinical pattern and epidemiological analysis of amyotrophic lateral sclerosis in the Lodz Region in 1980-1986 by Mochecka-Thoelke, A

    Published in Neurologia i neurochirurgia polska (01-03-1994)
    “…112 case of ALS in the Province of Lódź diagnosed between 1980-1986 are analysed. The male: female ratio was 1.5:1. The median age at onset was 54.8. The peak…”
    Get more information
    Journal Article
  12. 12
  13. 13
  14. 14